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Abstract
Nab-paclitaxel is an albumin-bound 130-nm particle form of paclitaxel that has shown an improved efficacy in ex-
perimental tumor models and clinical studies compared with solvent-based paclitaxel. Anti–vascular endothelial
growth factor A (VEGF-A) antibody bevacizumab is known to enhance antitumor activity of cytotoxic drugs. This
study evaluated the effects of combined nab-paclitaxel and bevacizumab therapy on growth and metastatic spread
of orthotopic breast tumors. Cytotoxic and clonogenic assays measured VEGF-A–dependent modulation of nab-
paclitaxel toxicity on cultured tumor cells. Antitumor effects were assessed in mice with luciferase-tagged, well-
established MDA-MB-231 tumors (250–310 mm3) treated with one, two, or three cycles of nab-paclitaxel (10 mg/
kg, daily for five consecutive days), bevacizumab (2–8 mg/kg, twice a week), or with combination of both drugs.
VEGF-A protected MDA-MB-231 cells against nab-paclitaxel cytotoxicity, whereas bevacizumab sensitized cells to
the effect of the drug. Combined bevacizumab and nab-paclitaxel treatment synergistically inhibited tumor growth
and metastasis resulting in up to 40% of complete regressions of well-established tumors. This therapy also de-
creased the incidence of lymphatic and pulmonary metastases by 60% and 100%, respectively. The significant
increase in the cure of tumor-bearing mice in the nab-paclitaxel/bevacizumab combined group compared with
mice treated with single drugs strongly advocates for implementing such strategy in clinics.
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Introduction
Paclitaxel is a potent cytotoxic agent that is widely used against var-
ious refractory and metastatic malignancies [1,2]. Paclitaxel induces
the assembly of tubulin subunits and prevents microtubule depoly-
merization, thereby disrupting normal microtubule reorganization,
leading to G2/M cell cycle arrest [3]. In addition, paclitaxel enhances
apoptosis of cancer cells by promoting the phosphorylation and
down-regulation of prosurvival protein bcl-2 [4]. Recently, the clin-
ical use of paclitaxel has been significantly improved by formulating
this drug in Cremophor-free, albumin-bound, 130-nm particles
named nab-paclitaxel (paclitaxel protein-bound particles for inject-
able suspension or nab-paclitaxel also named Abraxane; Abraxis Bio-
Science, Inc., Los Angeles, CA). Both clinical [2,5] and experimental
studies demonstrated several advantages of nab-paclitaxel compared
to conventional solvent-based paclitaxel (Taxol; Bristol-Myers Squibb
Co., Princeton, NJ) [6,7] and docetaxel (Taxotere; Sanofi Aventis,
Bridgewater, NJ). The main advantages include linear pharmacoki-
netics, high tumor retention, improved antitumor efficacy, and re-
duced toxicity [8] because of the elimination of Cremaphor [2].
However, the tumor response even to the improved formulation of
paclitaxel is typically only 30% to 35% [7].
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Several mechanisms may account for resistance to nab-paclitaxel
treatment in some tumors, and targeting these mechanisms would
greatly enhance antitumor efficacy. One mechanism that might increase
tumor resistance to chemotherapy is increased expression of vascular
endothelial growth factor A (VEGF-A) that is primarily responsible
for the vascularization of solid tumors [9,10]. Although some studies
have reported inhibition of VEGF-A by paclitaxel [11] and docetaxel
[12,13] suggesting that these drugs are antiangiogenic in vivo [14,15],
the overwhelming body of evidence indicates induction rather than
suppression of VEGF-A after cytotoxic treatments. Chemodrugs that
have been shown to induce VEGF-A expression include paclitaxel
[16], docetaxel [16], carboplatin [17], cisplatin [18], 5-fluorouracil
[19], dacarbazine [20], and anthracyclines [21]. Chemotherapy-induced
VEGF-A production is possibly mediated by mitogen-activated pro-
tein kinase kinase/extracellular regulated kinase pathway [16], nuclear
factor-κB [22], and phosphatidylinositol 3 kinase/AKT pathways
[23,24] that are typically activated in response to stress in both tu-
mor [18,19] and endothelial cells [17]. In vivo, VEGF-A production
and subsequent angiogenesis can also be augmented by chemotherapy-
associated hypoxia [18,25] that results from tumor cell death and vascu-
lar collapse in the drug-affected areas. In addition, docetaxel-induced,
hypoxia-inducible factor 1 alpha–independent increase in VEGF-A has
been also reported in patients with chemoresistant breast carcinoma [26].
VEGF-A induced by chemotherapy can promote survival of endo-
thelial [12] and tumor cells [27], thus protecting both neoplastic and
stroma cells from cytotoxic death while supporting angiogenesis in vivo.
Thus, activation of proangiogenic programs by low concentrations of
chemotherapeutic drugs might be responsible, in part, for tumor resis-
tance to chemotherapy and tumor regrowth after initial drug-mediated
suppression. This concept is supported by the recently recognized
autocrine-positive VEGF-A·VEGF receptors loop detected in malig-
nant cells of the lung [28], breast [28], colon [29], and renal [30]
tumors. Coexpression of VEGF-A and its tyrosine kinase [29] or non-
tyrosine kinase [31] cognate receptors in neoplastic cells enhances tu-
mor motility [32] and plays a major role in tumor cell survival under
adverse conditions. Taken together, these observations lend to the
idea that antitumor and antimetastatic effects of chemotherapy can
be both potentiated and sustained by concurrent administration of
agents that disrupt VEGF-A signaling. Not surprisingly, the combi-
nation of cytotoxic drugs including paclitaxel with VEGF-A targeting
agents reportedly improved tumor response to chemotherapy [33,34]
and increased patient survival [35].
An additional reason for combined therapy is the need to decrease
high oncotic and intratumoral pressure that prevent tumor penetra-
tion by chemoagents, including that of nab-paclitaxel [36]. Seques-
tration of VEGF-A by bevacizumab, a specific VEGF-A–neutralizing
monoclonal antibody [10,37] (Avastin; Genentech, Inc., San Francisco,
CA), increased vessel stability and reduced both protein extravasation
and intratumoral pressure, thus increasing concentration of chemo-
agents within the tumor mass [38]. Response to paclitaxel improved
in patients treated with bevacizumab and paclitaxel combined com-
pared with paclitaxel alone [39]. However, vessel stabilization was gen-
erally transient, lasting 5 to 8 days before the tumor reverted to
abnormal vessel structure [40] with poor transport of molecules, thus
requiring chronic bevacizumab treatment. This could lead to overprun-
ing of the vasculature, resulting in reduced blood flow and intratumoral
penetration. Understanding this paradox and developing combinatorial
treatments that include targeting angiogenic response to chemotherapy
will greatly increase the efficacy of the treatment and durability of the
tumor response to chemodrugs. We therefore performed a series of
studies in orthotopic breast cancer models examining the combined
effects of a novel paclitaxel, nab-paclitaxel, and anti–VEGF-A anti-
body, bevacizumab, on tumor growth and on hematogenous and lym-
phatic metastases.
Materials and Methods
Materials
Dulbecco’s modified Eagle’s medium (DMEM), glutamine, so-
dium pyruvate, and nonessential amino acids were obtained from Life
Technologies (Grand Island, NY). Human recombinant VEGF-A pro-
tein (VEGF-A165 isoform) was purchased from PeproTech (Rocky
Hill, NJ). Mouse anesthetic cocktail was a mixture of ketamine (Fort
Dodge Animal Health, Fort Dodge, IA), xylazine (Phoenix Scientific,
Inc., St. Joseph, MO), and sterile water. Endotoxin-free sterile saline
was purchased from Sigma (St. Louis, MO).
Study Drugs
Paclitaxel albumin-bound particles for injectable suspension (nab-
paclitaxel or Abraxane) was obtained from Abraxis BioScience, Inc.,
Los Angeles, CA. Drugs were reconstituted in saline, prepared fresh
daily as required, and given within 1 hour of preparation. Bevacizu-
mab (Avastin), humanized anti–VEGF-A antibody, manufactured by
Genentech, Inc., was obtained from a local pharmacy.
Human MDA-MB-231 and MDA-MB-435 Carcinoma Cell
Lines and Their Luciferase Derivatives
Luciferase-expressing cell line derivative of MDA-MB-231, 231-
Luc+, has been extensively characterized in vitro and in vivo in prior
studies and repeatedly assessed of reproducible spontaneous lym-
phatic and pulmonary metastases on orthotopic implantation in im-
munodeficient mice [41]. Luciferase-tagged MDA-MB-435 derivative
subline was a generous gift from Dr. Sierra (Universitaria de Bell-
vitge, Barcelona, Spain). Cells were cultured at 37°C in an incubator
gassed with 10% CO2 in humidified air. The culture medium for cell
lines consisted of DMEM supplemented with 5% fetal bovine se-
rum, 2 mM glutamine, 1 mM sodium pyruvate, and nonessential
amino acids. Tumor cells were harvested for passage by washing
the monolayer with PBS, followed by 3 to 4 minutes of exposure
to EDTA (0.5 mM) diluted in PBS. Cells were subcultured twice
weekly and routinely tested for mycoplasma using an immunodetec-
tion kit from Roche Diagnostics GmbH (Penzberg, Germany).
Total RNA Extraction and Reverse Transcription–Polymerase
Chain Reaction Analysis
Total RNA was extracted using an RNeasy Mini kit (Qiagen, Va-
lencia, CA) and reverse-transcribed using RTG You-Prime Reaction
beads (Amersham, Piscataway, NJ) and random hexamer primers (In-
vitrogen, Carlsbad, CA). Primer sequences, which were designed us-
ing GeneRunner software, are available on request. Human Universal
cDNA (SuperArray, Frederick, MD) and a housekeeping gene,
namely, β-actin, were used as positive controls. Standard end point
reverse transcription–polymerase chain reaction (RT-PCR) was per-
formed and analyzed using a FluroChem5500 (Alpha Innotech, San
Leandro, CA) imaging system and software.
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Western Blot Analysis
Antibodies for Western blot analysis were obtained from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA). Cells were lysed in cell
lysis buffer (50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1 mM
EDTA, 1% Triton X-100, 0.1% SDS, PMSF, and protease inhibi-
tors). Thirty micrograms of total protein was separated on 12%
SDS-PAGE gels and transferred to nitrocellulose membranes (Pierce,
Rockford, IL). Membranes were blocked for 1 hour with 5% BSA in
0.1% Tween 20 in Tris-buffered saline and were incubated with pri-
mary antibodies overnight at 4°C. Membranes were extensively
washed and incubated with horseradish peroxidase–labeled secondary
antibodies from Jackson Immunoresearch Laboratories (West Grove,
PA) for 60 minutes before development using Super Signal Chemi-
luminescence substrate (Pierce).
Cytotoxic Assay
MDA-MB-231 cells were seeded at a density of 50,000 cell per
well in 24-well plates and allowed to attach for 2 hours before treat-
ment. Cells were treated with nab-paclitaxel alone (0.2 to 50 nM),
VEGF-A165 alone (20 ng/ml), or with combination of nab-paclitaxel
and anti–VEGF-A antibody, bevacizumab (10 μg/ml). Control wells
received an equal volume of growth medium. After 72 hours, cells
were dislodged by EDTA–saline solution, and viable cells were enu-
merated using the Trypan blue exclusion method. Each experimental
condition was tested in triplicate and reproduced in two separate ex-
periments. The results are presented as percent of viable cells ± SD of
the mean cell number in control wells.
Clonogenic Assay
Cells were seeded in triplicate at a density of 10,000 live cells per
100-mm dish containing 10 ml of complete medium. Two hours after
seeding, cells were treated with nab-paclitaxel (10 nM), VEGF-A
(20 ng/ml), bevacizumab (10 μg/ml), and combinations of nab-
paclitaxel with either VEGF-A or bevacizumab diluted in 20 μl of
growth medium. Control plates received medium only. After 14 days
of incubation at 37°C, plates were washed with PBS and stained with
0.5% crystal violet dissolved in absolute methanol. Images were taken
using an Alpha Innotech image analyzer FluroChem5500, and colonies
with diameter >0.05 mm were enumerated using Alpha Ease FC soft-
ware. The results are presented as the mean survival fraction derived
from averaged values of three plates per experimental group ± SD.
Mouse Models of Human Breast Cancer
Orthotopic model of luciferase-tagged MDA-MB-231 cells was
previously described [41]. Briefly, 4 × 106 cells and 50% Matrigel
were implanted into the mammary fat pad of 4- to 6-week-old female
nu/nu mice (Harlan Sprague-Delaney, Indianapolis, IN). Every 2 to
3 days, perpendicular tumor diameters were measured by digital cal-
iper and used to calculate tumor volume according to the formula: vol-
ume = Dd 2π/6, where D equals larger diameter and d equals smaller
diameter. The 231-Luc+ tumors and nontransfected parental cell line
had an identical proliferation rate. Animal care was in accordance with
institutional guidelines.
Treatment of Tumor-Bearing Mice with Nab-paclitaxel
and Bevacizumab
Mice bearing 231-Luc+ tumors of 200 to 250 mm3 in volume
were randomized into groups (5–10 per group) and treated with sa-
line, nab-paclitaxel alone [10 mg/kg, intravenously (i.v.), daily for
five consecutive days (qdx5)], bevacizumab alone [4 mg/kg, intraperi-
toneally (i.p.), twice a week], or nab-paclitaxel followed by bevaci-
zumab. Nab-paclitaxel treatment was given once for five consecutive
days (one cycle) or repeated two or three times with 1 week of rest
interval (two and three cycles). The averaged tumor volume of mice
treated with three cycles of combined therapy was 310 mm3. Beva-
cizumab treatment began 24 hours after the first injection of nab-
paclitaxel, with a dose of 2, 4, or 8 mg/kg dissolved in 0.1 ml of
sterile endotoxin-free saline and injected i.p. twice a week, for a total
period of 5 weeks. The control group received saline, injected i.v. or
i.p. (0.1 ml) on the same days as nab-paclitaxel and bevacizumab
treatments, respectively. To allow maximal development of metastatic
foci, mice were killed when the average tumor volume in the control
group reached 2000 mm3, and tumor metastasis was determined by
measuring luciferase activity in tissue extracts derived from 10 lymph
nodes (LNs) and both lobes of lungs. All experiments were repeated
at least twice with similar results.
Detection of Metastases By Measuring Luciferase Activity
Lymph nodes and lungs were excised, washed in PBS, and homog-
enized in 0.35 ml of cold cell culture lysis reagent buffer (Promega,
Madison, WI) containing protease inhibitor cocktail and PMSF (Sigma,
MO). Cell debris was removed by centrifugation. Protein concentra-
tions of cleared lysates were determined by Bradford assay (Bio-Rad,
Hercules, CA). Fifty microliters of Luciferase Assay Reagent (Promega)
was mixed with 10 μl of lysate, and a 10-second average of lumines-
cence was detected using a single-tube luminometer (Berthold Tech-
nologies, Bad Wildbad, Germany). Cell culture lysis reagent buffer
without tissue homogenates and LNs or lungs of non–tumor-bearing
mice were considered as background and subtracted from the results.
The net results are expressed as relative light units normalized per mil-
ligram of total protein. To assess incidence of metastasis, extracts that
had a luminescence signal of 400 light units above background (ap-
proximately 100 relative light units) were rated positive. This value
was chosen because it was the minimal signal reproducibly detected
above background in metastatic tissues, independently confirmed by
immunohistochemical detection.
Statistical Analysis
Statistical analysis was performed using GraphPad InStat (GraphPad,
Inc., San Diego, CA) or SPSS 14.0 (SPSS, Inc., Chicago, IL). Results
were expressed as mean ± SE. Statistically significant differences of
mean tumor volume among experimental groups were analyzed using
a nonparametric Kruskal–Wallis test. Statistically significant differences
of LN and lung metastases were analyzed by Fisher’s exact test or
Mann-Whitney U test. Metastatic burden was transformed with a
log transformation and analyzed using analysis of variance with Tukey’s
follow-up comparisons.
Results
Low Concentrations of Nab-paclitaxel Increase VEGF-A
Production in Breast Carcinoma Cells
To access the response of tumor cells toward chemotherapy, we
first investigated whether VEGF-A expression in cultured MDA-
MB-231 cells could be up-regulated by nab-paclitaxel in vitro. As
shown in Figure 1A, nab-paclitaxel applied at concentrations below
10 nM increased VEGF-A mRNA expression measured by quantita-
tive RT-PCR (QRT-PCR) by two- to three-fold in a dose-dependent
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manner. Nab-paclitaxel at concentrations more than 20 nM de-
creased VEGF-A mRNA production compared with medium con-
trol, likely due to the cytotoxic effect of nab-paclitaxel. The changes
in VEGF-A mRNA production as determined by QRT-PCR were
confirmed by measuring secreted VEGF-A protein with ELISA (Fig-
ure 1B). Moreover, intracellular VEGF-A protein, as detected by West-
ern blot analysis, was also proportionally increased after exposure to
2.5 to 30 nM of nab-paclitaxel (Figure 1C ). Similar results have been
obtained with MDA-MB-435 cells. These results show that low con-
centrations of nab-paclitaxel could directly stimulate both VEGF-A
mRNA and protein production in tumor cells in vitro.
Some Breast Carcinoma Lines Express VEGF-A Receptors
Suggesting an Existence of Autocrine Loop
MDA-MB-231 and MDA-MB-435 have been previously reported
to express functional VEGF-A receptors that have been implicated in
the generation of VEGF-A–dependent autocrine loops [31,42,43].
Both tyrosine kinase VEGF-A receptors [43] and neuropilin-1
(NP-1) have been detected in MDA-MB-231 [31] and to a lesser ex-
tent, in MDA-MB-435 [31,42]. We have used luciferase-tagged deri-
vatives of these lines that have not been analyzed previously either for
the expression of VEGF-A receptors by neoplastic cells or for evidence
of VEGF-A–driven autocrine regulation. In accord with published
studies analyzing parental lines [43], three VEGF-A isoforms were de-
tected in both 231-Luc+ and 435-Luc+ with predominant expression
in the 231 derivative line (Figure 2A). VEGF-A receptors, VEGFR-2 and
NP-1, were strongly detected in 231-Luc+ and weakly in 435-Luc+
line (Figure 2A). Expression of neuropilin-2 (NP-2) was not previ-
ously examined in either 231-Luc+ or 435-Luc+ line. We detected
strong NP-2 expression in 435-Luc+ cells only (Figure 2). This profile
of mRNA expression was confirmed by immunohistochemical detec-
tion of the targets proteins (Figure 2B). As has been suggested pre-
viously [44,45], coexpression of VEGF-A and its specific receptors
in either parental human breast carcinoma or metastatic derivatives
suggests an autocrine role for VEGF-A in the regulation of vital tumor
cell activities such as proliferation and survival. Both of these activ-
ities can contribute to the resistance of tumor cells to the action of
cytotoxic drugs.
Anti–VEGF-A Antibody, Bevacizumab, Abolished the
Protective Effect of VEGF-A Against Paclitaxel Cytotoxicity on
Cultured Breast Carcinoma Cells In Vitro
Because VEGF-A protects endothelial cells against chemotherapies
[12], we examined whether it also enhances survival of VEGF-A re-
ceptors positive tumor cells exposed to cytotoxic drugs. We hypoth-
esized that low concentrations of nab-paclitaxel might induce
VEGFR signaling leading to enhanced tumor cell survival and, sub-
sequently, to decreased therapeutic efficacy. To test this hypothesis,
we measured the cytotoxicity and clonogenic survival of 231-Luc+
cells treated with nab-paclitaxel (0.2 to 50 nM), VEGF-A (20 ng/ml),
and bevacizumab (10 μg/ml) alone or in combination (Figure 3). In
the cytotoxic assay, the IC50 of nab-paclitaxel for cultured 231-Luc
+
cells was determined as 9.9 nM (Figure 3A). A 50-nM dose of nab-
paclitaxel reduced the cell number by 90% compared with culture
medium–only control cells. Exogenous VEGF-A shifted the IC50
to 14.2 nM, thus decreasing the efficacy of a nab-paclitaxel–mediated
cytotoxic effect. In contrast, neutralization of VEGF-A by bevacizu-
mab caused an opposite effect by shifting the IC50 to 2.27 nM, thus
strongly increasing nab-paclitaxel cytotoxicity. The most conspicuous
changes in shifting cell sensitivity to nab-paclitaxel were observed in
the IC50 range. This suggests that very low concentrations of cyto-
toxic drugs may not be sufficient for eliciting VEGF-A signaling,
Figure 1. Low concentrations of nab-paclitaxel elicit VEGF-A production in cultured breast carcinoma cells and in breast tumors in vivo.
(A) MDA-MB-231 cells were exposed to indicated concentrations of nab-paclitaxel for 72 hours and analyzed for mRNA expression of
VEGF-A by QRT-PCR. (B) Tumors from mice treated with escalating doses of nab-paclitaxel were homogenized and analyzed for the
presence of human VEGF-A protein by ELISA. (C) Lysates of cells treated by nab-paclitaxel at indicated doses were separated on SDS-
PAGE, transferred to nitrocellulose membrane, and probed for expression of VEGF-A. β-Actin was also detected on the same blot and
shown as a loading control. Note the increase in VEGF-A expression in lysates of nab-paclitaxel–treated cells relative to control.
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whereas cell death at high drug doses occurs before VEGF-A can play
a protective role.
We also examined single-cell survival of 231-Luc+ cells after treat-
ment with nab-paclitaxel, VEGF-A, and bevacizumab alone or in
combination. Exposure to 10-nM nab-paclitaxel reduced cell survival
by 43%, whereas addition of VEGF-A (20 ng/ml) increased survival
by 49%, compared with medium-treated control cells (Figure 3B).
Bevacizumab alone had relatively modest effect by decreasing cell
survival by 23% compared with control. Importantly, VEGF-A vir-
tually negated the cytotoxic effect of the nab-paclitaxel, whereas com-
bination of bevacizumab and nab-paclitaxel greatly potentiated the
drug’s efficacy resulting in a 76% decrease in the number of colo-
nies compared with vehicle-treated controls. The differences in cell
survival after treatment with nab-paclitaxel/bevacizumab combina-
tion and all other groups were statistically significant (P < .05 by
Student’s t-test). Similar effects were observed in experiments with
Figure 2. Luciferase-tagged derivatives of human breast carcinoma lines express VEGF-A receptors. (A) Total RNA was isolated from
231-Luc+ and 435-Luc+ cells and used to synthesize cDNA for PCR amplification using primers for VEGF-A and its receptors. Universal
human cDNA was used as a positive control. Amplification of β-actin is shown as a reference for housekeeping gene expression and for
comparing a relative gene target expression in 231-Luc+ and 435-Luc+ cell lines. (B) 231-Luc+ and 435-Luc+ cells were stained with
anti–human VEGFR-2 and anti–NP-1 and NP-2 antibodies followed by appropriate horseradish peroxidase–conjugated secondary anti-
bodies and DAB development. Arrows indicate positively stained cells. Brown color precipitate was not developed on the application of
secondary antibodies alone. Original magnifications, ×400.
Figure 3. Nab-paclitaxel cytotoxicity is negated by VEGF-A and is enhanced by anti–VEGF-A antibody bevacizumab. (A) MDA-MB-231
cells were treated with nab-paclitaxel only (black circles), with nab-paclitaxel and VEGF-A (20 ng/ml, white circles), with a mixture of nab-
paclitaxel and bevacizumab (10 μg/ml, black triangles) or left untreated. Seventy-two hours later, cell number and viability was deter-
mined using Trypan blue exclusion method. The results were averaged from triplicate per treatment and presented as percentage of
viable cells ± SD from the cell number in untreated wells. (B) The survival capacity of MDA-MB-231 cells was determined by seeding
cells at the low density of 10,000 per 100-mm dish followed by treatment with nab-paclitaxel (10 nM), VEGF-A (20 ng/ml), bevacizumab
(10 μg/ml), a combination of nab-paclitaxel with VEGF-A, or bevacizumab given at the same concentrations as a single drug. The results
are presented as the mean number of colonies per dish ± SD, detected 14 days after seeding.
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MDA-MB-435 and 435-Luc+ cells. These findings in the models
of tumor cell responses to chemotherapy in vitro suggest that nab-
paclitaxel/bevacizumab combination strategy could significantly im-
prove therapeutic outcome in vivo.
Bevacizumab Potentiates Nab-paclitaxel Inhibition of Tumor
Growth In Vivo
The in vitro results suggested that enhanced VEGF-A production
by paclitaxel-treated cells might contribute to tumor chemoresistance
through stimulation of angiogenic and cell survival pathways. On the
basis of these findings, we hypothesized that neutralizing VEGF-A
concurrently with chemotherapy would enhance antitumor efficacy
and sustain therapeutic gains after cessation of the treatment. To test
this hypothesis, we examined the antitumor efficacy of nab-paclitaxel
alone and in combination with bevacizumab in an orthotopic model
of luciferase-tagged human breast carcinoma, MDA-MB-231 (231-
Luc+). This model is extensively characterized in our laboratory and
is known to reproducibly generate LN and pulmonary metastases in
100% and 70% of tumor-bearing mice, respectively [41]. Moreover,
recent studies in our laboratory established that 50% of control mice
(n = 15) have metastases in contralateral LN and 40% of animals
have metastasis to the brain. To our knowledge, this is the first de-
scribed animal model of orthotopically implanted human breast car-
cinoma that faithfully mimics the severity of the human metastatic
disease including spread not only to the proximal LN but also to the
contralateral LN, the lungs, and the brain.
The first experiment was conducted with nab-paclitaxel (10 mg/kg)
administered i.v. qdx5 either alone or combined with bevacizumab
(2 mg/kg, i.p., twice a week, for the duration of the experiment). Com-
bination therapy showed an additive effect in the suppression of tu-
mor growth as evidenced by the stronger reduction of tumor volume
(87.7% vs 71.3% and 54.1% for nab-paclitaxel and bevacizumab
monotherapies, respectively, P < .05; Table 1). Tumor growth delay
(TGD) was also increased from 13 and 20 days for bevacizumab and
nab-paclitaxel, respectively, to 33 days in mice treated with combined
therapy (Figure 4; Table 1). However, despite this evidence of im-
proved tumor responses after combination therapy, no complete re-
sponses were observed in any of the groups. Moreover, tumors regrew
in 100% of the treated mice within 60 to 70 days after cessation of
either single or combined therapies (Table 1; Figure 4).
Optimized Regimen of Bevacizumab and Nab-paclitaxel
Combined Therapy Potentiates and Sustains Efficacy of
Cytotoxic Therapy
To further improve tumor responses, we modified the regimen by
increasing the dose of bevacizumab from 2 mg/kg to 4 and 8 mg/kg
and the number of nab-paclitaxel treatments to two or three cycles
given with 1 week of interval between each cycle. The change in reg-
imen was possible because both bevacizumab and nab-paclitaxel have
relatively high maximum tolerated doses. This is particularly signifi-
cant for nab-paclitaxel whose maximum tolerated dose is 2.5-fold
higher than that of Taxol in both rodents [6,46] and in cancer pa-
tients [47–49]. This property of nab-paclitaxel allowed us to admin-
ister repetitive chemotherapy cycles without causing unacceptable
toxicity as judged by weight loss (more than 20% of the body weight)
and behavioral changes. Addition of bevacizumab to nab-paclitaxel
did not change the safety profile, although increased toxicity for the
combined Taxol and bevacizumab therapy has been documented in
human subjects.
We performed three experiments with one, two, or three cycles of
nab-paclitaxel. Those results are presented in Figure 4, A, B, and C,
respectively. The average tumor volume before the treatments was
approximately 250 mm3 in the experiments with one and two cycles
(Figure 4, A and B), and approximately 310 mm3 in the experiment
with three cycles of chemotherapy (Figure 4C ). The increase of bev-
acizumab from 2 to 4 mg/kg showed some improvement in tumor
suppression but further escalation to 8 mg/kg had no additional ef-
fect (Table 1). Bevacizumab alone had no effect in TGD in any of the
experiments. In contrast, significantly higher tumor inhibition was
observed after two cycles of nab-paclitaxel compared with one cycle
(95.11% vs 71.33%, P < .005; Table 1). Notably, two cycles of nab-
paclitaxel delayed tumor regrowth for longer than 65 days after treat-
ment compared with only 20 days after one cycle (Table 1). However,
the most significant improvement in tumor response was observed on
the combination of the two drugs: 40% of mice treated with nab-
paclitaxel and either 4 or 8 mg/kg of anti–VEGF-A antibody (total
Table 1. Effect of Nab-paclitaxel, Bevacizumab, and Combined Therapies on Tumor Growth in the MDA-MB-231-Luc+ Tumor Model.
Treatment Bevacizumab Dose (mg/kg) Mean Tumor Volume (mm3) % TGI† vs Control TGD‡ vs Control % Complete Responses§
One cycle of treatment
Control 2079 ± 287
Bev* 2 953 ± 127 54.16 13 0
ABX* 596 ± 98 71.33 20 0
ABX + Bev* 2 255 ± 46 87.73 33 0
Two cycles of treatment
Control 2391 ± 432 0
Bev 4 2089 ± 251 12.56 7 0
ABX 117 ± 38 95.11 >65 0
ABX + Bev 2 138 ± 42 94.23 >65 20
ABX + Bev 4 60 ± 17 97.49 >65 40
ABX + Bev 8 36 ± 16 98.49 >65 40
Three cycles of treatment
Control 1829 ± 241 0
ABX + Bev 4 52 ± 17 97.16 >107 80
*Bev, ABX, and Bev + ABX denote treatment with bevacizumab (4 mg/kg), nab-paclitaxel/Abraxane (10 mg/kg), and combination of the two drugs, respectively.
†TGI (tumor growth inhibition) is presented as percent reduction in the mean tumor volume in experimental groups compared with that in saline-treated control groups.
‡TGD (tumor growth delay) is defined as a number of days that delayed the mean tumor volume per group reaching 1000 mm3 as compared with the saline-treated control mice.
§Complete response was defined as the absence of palpable tumor at the original tumor injection site for the entire length of the experiments (75–110 days).
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N = 10) had complete and durable tumor regressions. Mice treated
with the same regimen with 2 mg/kg of bevacizumab had 20% com-
plete responses suggesting a trend toward dose dependency of the
ancillary anti–VEGF-A therapy.
No palpable or measurable tumors were observed in the cured
mice for the duration of the experiment (>65 days). Moreover, taking
advantage of the great sensitivity of luciferase detection of tumor cells
(one cell is equivalent to 10 light units), we measured luciferase ac-
tivity in the extract of the mammary fat pad used for 231-Luc+ cell
implantation. The extracts contained no measurable enzymatic activ-
ity indicating complete tumor eradication in 231-Luc+ mice. The re-
markable effect on eradication of well-established tumors (>200 mm3
in volume before the treatment) was reproduced in the third exper-
iment in which the number of nab-paclitaxel cycles was increased to
three and bevacizumab’s dose fixed to 4 mg/kg. Tumor regrowth was
observed in one mouse in the treated group (Figure 4C; three cycles)
but only after 107 days after treatment. After three cycles, tumor
growth was suppressed 5.35- and 1.64-fold days longer, compared
with one and two cycles, respectively. Apart from one escapee, most
of the mice (80%) treated with this combinatory regimen had com-
plete regressions (Table 1; Figure 4C). Thus, three cycles of the com-
bined therapy doubles the number of complete responses compared
with two cycles (40%), whereas a one-cycle combination treatment
had no capacity to eradicate tumors (Table 1; Figure 4A). These
data indicate that repetitive delivery of the well-tolerated dose of
nab-paclitaxel (10 mg/kg) supplemented with anti–VEGF-A therapy
can eradicate well-established tumors.
Nab-paclitaxel/Bevacizumab Combination Therapy
Significantly Suppresses Both Lymphatic and
Pulmonary Metastases
Metastasis is the most devastating consequence of the malignant
disease. The 231-Luc+ model induces both intratumoral [41] and
peritumoral [50] lymphatic vessels and first metastasizes to LNs with
subsequent spread to visceral organs [41]. Because one tumor cell
produces 10 light units on exposure to luciferin, as few as 50 cells
can reliably be detected in the lysate samples. This model, therefore,
allows sensitive assessment of the antimetastatic potential of nab-
paclitaxel/bevacizumab combination therapy with regard to both in-
cidence and total metastatic burden. These parameters were analyzed
in all experiments by measuring luciferase activity in tissue extracts
from ipsilateral LNs and lungs. Measurements of luciferase activity in
contralateral LNs and brain extracts were additionally performed af-
ter three cycles of combined treatment.
No effect on metastasis was observed after one cycle of nab-paclitaxel,
bevacizumab or combined therapy (data not shown). This is despite
the fact that one cycle of combination therapy inhibited tumor
growth by 87% and delayed regrowth of primary tumors by 33 days
(Table 1). In contrast, two cycles of the combined therapy, but
not the single treatments, reduced the burden and the incidence in
the proximal LN by 80% and 60%, respectively (Table 2; Figure 5).
Notably, two cycles of the combined therapy eliminated pulmonary
metastases in 100% of the treated mice (n = 5) whereas monothera-
pies were ineffective (Table 2). Escalation of the bevacizumab dose
(2, 4, or 8 mg/kg) had no significant impact on the overall effect
(Figure 5), although the higher doses of the antibody treatment (4
or 8 mg/kg) tend to be more effective in all experiments. Bevacizu-
mab at 4 mg/kg was used to study the effect of a three-cycle com-
bination therapy. In this experiment, contralateral LN and brain
metastases were eliminated in 100% of the treated mice (n = 5),
whereas ipsilateral LN and lung metastases were eradicated in 80%
of the mice (Table 2; Figure 5). All differences in the average meta-
static burden between control- and the combined therapy–treated
groups were statistically significant for all organs examined in this
study (Table 2).
In summary, stark differences were observed between a completely
ineffective one-cycle treatment, singular or combined, and the two-
or three-cycle therapies that drastically reduced both incidence and
the averaged metastatic burden. Bevacizumab seems to be essential
for the effective suppression of metastasis by nab-paclitaxel as only
the combined therapy group displayed appreciable antimetastatic
effect (Table 2). These results suggest that repetitive cycles of nab-
paclitaxel when administered concurrently with bevacizumab have
a strong potential to eradicate breast cancer metastasis in ipsilateral
LN and other metastatic sites.
Discussion
The main findings of this study are that tumor cells respond to
cytotoxic stress by producing VEGF-A and that neutralization of
Figure 4. Bevacizumab significantly improves antitumor effect of nab-paclitaxel in vivo. (A, B) Mice bearing orthotopic MDA-MB-231-Luc+
tumors of 200 to 250 mm3 were treated with one or two cycles of saline, nab-paclitaxel alone (10 mg/kg, qdx5 cycle), bevacizumab alone
(4 mg/kg), or both drugs. (C) A similar experiment was performed in mice bearing∼310 mm3 tumors that were treated with three cycles of
nab-paclitaxel and concurrent bevacizumab or with saline control. The results are presented as the mean tumor volume ± SE per group
measured at indicated days after treatment.
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VEGF-A during chemotherapy is essential for sustaining inhibition
of both primary tumors and metastasis. Moreover, synergy developed
between nab-paclitaxel and anti–VEGF-A antibody has strong po-
tential to eradicate lymphatic- and organ-specific metastases that
were not achievable by using either of these drugs alone.
Our in vitro studies demonstrated that nontyrosine kinase and tyro-
sine kinase VEGF-A receptors are present in both MDA-MB-231 and
MDA-MB-435 cells. Coexpression of VEGF-A and its cognate receptors
in malignant cells have been previously suggested as responsible for
the formation of positive circuit that protects tumor cells from adverse
effects of chemotherapy [24,44]. This presumably occurs because
VEGF-A binding to VEGFR-2 activates the AKT pathway and increases
the expression of prosurvival factors, such as bcl-2 [51] and survivin
[52]. A previous study by Sweeney et al. [12] showed that VEGF-A pro-
tects endothelial cells from the cytotoxic effect of docetaxel. In accord
with the published findings, we observed that VEGF-A significantly
reduces nab-paclitaxel cytotoxicity whereas anti–VEGF-A antibody,
bevacizumab, abrogates the VEGF-A dependent protective effect on
tumor cells (Figure 3). Thus, over-expression of VEGF-A induced by
cytotoxic therapy not only protects endothelial cells and increases angio-
genesis, but also can prolong survival of the damaged neoplastic cells
during a vulnerable period of tumor vasculature regeneration.
Table 2. Effect of Nab-paclitaxel, Bevacizumab, and Combined Therapy on Metastatic Incidence and Burden.
Tissue Treatment Two Cycles of Nab-paclitaxel Three Cycles of Nab-paclitaxel
Incidence† Burden‡ P§ Incidence Burden P
Proximal LN Control 10/10 (100%) 31.1 ± 9.4 5/5 (100%) 123.7 ± 73.0
Bev* 5/5 (100%) 31.8 ± 9.1 NS¶ ND
ABX* 5/5 (100%) 26.0 ± 12.8 NS ND
Bev + ABX* 2/5 (40%) 6.0 ± 4.3 .022** 1/5 (20%) 16.7 ± 3.4 .013**
Contralateral LN Control ND# 3/5 (60%) 72.3 ± 47.0
Bev + ABX ND 0/5 (0%) 0 <.001**
Lungs Control 7/10 (70%) 7.7 ± 2.2 5/5 (100%) 21.5 ± 9.4
Bev 3/5 (100%) 3.2 ± 2.0 NS ND
ABX 4/5 (100%) 7.9 ± 2.7 NS ND
Bev + ABX 0/5 (0%) 0 .025** 1/5 (20%) 5.7 ± 1.4 .041**
Brain Control ND 2/5 (40%) 1.3 ± 0.8
Bev + ABX ND 0/5 (0%) 0 <.001**
*Bev, ABX (nab-paclitaxel), and Bev + ABX denote treatment with bevacizumab (4 mg/kg), nab-paclitaxel (10 mg/kg), and combination of the two drugs, respectively.
†Incidence is defined as number of mice with LN or lung metastasis per total number of mice with tumors in each experimental group. Percentage of mice with metastases is shown in parentheses.
‡Burden is presented as luciferase activity that was measured in extracts from 10 tumor-proximal or contralateral LNs and both lobes of lungs of each mouse. In the experiment with three ABX cycles, the
brain was analyzed as well. Samples that contained a minimum of 400 light units per 20-μl lysate were rated positive. Lysates from tissues of non–tumor-bearing mice produced a luminescence signal of
100 light units, which was considered as background and subtracted from positive values. Results are presented as the average amount of relative light units per group × 104 ± SE.
§P value was calculated by Fisher's exact test.
¶NS, nonsignificant; the difference between experimental and control groups does not reach statistical significance when analyzed by the Fisher's exact test.
#ND, not determined; in the experiment with three ABX cycles, the comparison was done between control and combination therapy only.
**Denotes statistical significance when log transformed values for metastatic burden in experimental and control groups were analyzed as described under the Materials and Methods section.
Figure 5. Effect of nab-paclitaxel and bevacizumab on lymphatic and systemic metastases. Mice were treated with either two (A) or
three (B) cycles of nab-paclitaxel alone, bevacizumab, or combination. Tumor-proximate LNs (n = 10) and lungs were harvested from
mice in experimental groups when the mean tumor volume in the saline-treated group reached 2 cm3. After three cycles of chemother-
apy, luciferase activity was determined in proximal and contralateral LNs, the lungs, and the brain. The results are presented as the mean
light units ×104 per group ± SE normalized per milligram of total protein. x-axis: Bevacizumab and ABX denote bevacizumab and nab-
paclitaxel, respectively. Numbers above and below the solid line separating ABX and bevacizumab indicate the drugs and a dose ex-
pressed in milligrams per kilogram used for the treatment of each of the experimental groups.
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Because of the crucial role of VEGF-A in chemoresistance [53],
VEGF-A targeting agents combined with chemotherapy show signif-
icantly improved tumor responses to treatment in a variety of preclin-
ical [33,35,54,55] and clinical studies [37,56]. In particular, the
anti–VEGF-A antibody bevacizumab, which was approved in 2004
for use in colorectal cancer [10] combined with 5-fluorouracil, leu-
covorin, oxaliplatin, or irinotecan, showed an additive or synergistic
effect when combined with chemotherapeutic drugs [33,55]. In
2006, bevacizumab in combination with carboplatin and paclitaxel
significantly improved overall survival and was approved as the first
line treatment of non–small cell lung carcinoma [57]. It has recently
been approved in February 2008 for metastatic breast cancer in
combination with paclitaxel (Bloom; www.medpagetoday.com).
Bevacizumab also showed efficacy against renal and ovarian cancers
when used as a single agent, and in patients with lung and breast
cancer when combined with chemotherapy [39]. Clinical studies
demonstrated that bevacizumab prolonged survival in previously un-
treated patients with advanced non–small cell lung cancer when
combined with paclitaxel/carboplatin [58]. The E2100 trial showed
that bevacizumab and paclitaxel combined therapy did not affect the
progression-free survival but doubled the response rate compared
with the treatment with paclitaxel alone [39,59]. Bevacizumab com-
bined with taxanes (paclitaxel or docetaxel) has also been shown
to significantly improve the cancer-related symptoms in patients with
refractory epithelial ovarian tumors, albeit this improvement was rela-
tively short-lived [56].
Our study, for the first time, demonstrated the effectiveness of
combination therapy with bevacizumab and nab-paclitaxel, the next
generation of taxanes in an experimental orthotopic and metastatic
model of human breast cancer. In vitro, sequestration of VEGF-A
by bevacizumab significantly enhanced nab-paclitaxel cytotoxicity
to breast carcinoma MDA-MB-231 cells leading to the restriction
of their clonogenic survival. The latter is crucially important for
the successful establishment of secondary tumors in distant organs
because of the inherent inefficiency of the metastatic process [60].
In vivo, bevacizumab synergistically increased the antitumor efficacy
of nab-paclitaxel against breast tumors. Although nab-paclitaxel alone
potently inhibited tumor growth, particularly after the two-cycle
therapy, tumor growth resumed in all mice regardless of the extent
of tumor suppression and TGD. Additionally, no complete regressions
were observed in any of the mice treated with either nab-paclitaxel
or bevacizumab alone. In contrast, nab-paclitaxel/bevacizumab combi-
nation therapy resulted in a significant number of complete responses.
Two qdx5 cycles of nab-paclitaxel alone and in combination with bev-
acizumab, showed more efficacy than a single cycle of monotherapy
or combined therapy, and retained limited toxicity. More importantly,
for the first time, the superior effect of the combined therapy was dem-
onstrated here not only for inhibition of the primary breast tumors but
also for suppression of both lymphatic- and organ-specific metastases.
The superior efficacy of nab-paclitaxel/bevacizumab combination
therapy might be explained by several mechanisms. First, bevacizu-
mab, although not highly effective as a monotherapy, may block the
reactionary angiogenesis by neutralizing nab-paclitaxel-induced
VEGF-A in tumor cells. Reactionary angiogenesis can be promoted
by multiple VEGF-A dependent mechanisms including recruitment
of proangiogenic macrophages and endothelial progenitor cells [61].
Second, as was recently suggested [62], anti–VEGF-A antibody ther-
apy might promote normalization of tumor vessels leading simulta-
neously to both increased drug delivery and decreased metastasis
[62]. This is because depletion of VEGF-A from the tumor environ-
ment eliminates the majority of structurally defective and malfunc-
tioning tumor microvessels. The few well-constructed vessels left
behind can function properly, potentially improving drug delivery
to the tumor [62]. Third, bevacizumab could block enhanced
VEGF-A production by tumor cells exposed to chemotherapy and
a variety of stress conditions, thus depriving a vital survival factor
from both endothelial and malignant cells [24]. Fourth, the combi-
nation of cytotoxic and anti-VEGF therapies has been reported to
reduce recruitment of tumor stem–like cells that may contribute to
recovery of tumor vasculature after partial response to chemotherapy
[63]. Finally, we have recently demonstrated in the orthotopic 231-
Luc+ breast carcinoma model that anti–VEGF-A therapy significantly
inhibits tumor lymphangiogenesis [41], which would explain the in-
ability of nab-paclitaxel alone to reduce lymphatic metastasis, and
shows an additional advantage of its combination with bevacizumab.
In summary, our data support the hypothesis that VEGF-A plays
a critical role in tumor recovery after nab-paclitaxel chemotherapy
either by acting directly on malignant cells expressing VEGF-A re-
ceptors or indirectly, by facilitating both angiogenesis and lymph-
angiogenesis [64] in drug-injured regions. We also conclude that
tumor regrowth and metastasis to LNs and lungs can be prevented
by the combination of cytotoxic therapy with VEGF-A–neutralizing
agents. Although the conclusions from experimental models must be
confirmed in multiple clinical settings, these results are in line with
the encouraging outcome of the recent limited clinical trials dem-
onstrating benefits of the nab-paclitaxel/bevacizumab combination
therapy in breast cancer patients [8,49]. The improved antitumor
efficacy and better safety profile of nab-paclitaxel over conventional
solvent-based paclitaxel [49,65] make it a promising candidate for
combining with anti–VEGF-A antibody. Our study demonstrates a
high efficacy of nab-paclitaxel and anti–VEGF-A combined therapy
against aggressive experimental metastatic breast tumors and strongly
advocates for the inclusion of bevacizumab as a standard modality
administrated concurrently with nab-paclitaxel therapy in clinics.
References
[1] Horwitz SB (1994). Taxol (paclitaxel): mechanisms of action. Ann Oncol 5
(Suppl 6), S3–S6.
[2] Damascelli B, Cantù G, Mattavelli F, Tamplenizza P, Bidoli P, Leo E, Dosio F,
Cerrotta AM, Di Tolla G, Frigerio LF, et al. (2001). Intraarterial chemotherapy
with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nano-
particles (ABI-007): Phase II study of patients with squamous cell carcinoma
of the head and neck and anal canal: preliminary evidence of clinical activity.
Cancer 92, 2592–2602.
[3] Li CJ, Li YZ, Pinto AV, and Pardee AB (1999). Potent inhibition of tumor sur-
vival in vivo by beta-lapachone plus taxol: combining drugs imposes different
artificial checkpoints. Proc Natl Acad Sci USA 96, 13369–13374.
[4] Sumitomo M, Asano T, Asakuma J, Asano T, Horiguchi A, and Hayakawa M
(2004). ZD1839 modulates paclitaxel response in renal cancer by blocking
paclitaxel-induced activation of the epidermal growth factor receptor–extracellular
signal–regulated kinase pathway. Clin Cancer Res 10, 794–801.
[5] ABI 007. Drugs R D 4, 303–305.
[6] Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, et al. (2006). Increased anti-
tumor activity, intratumor paclitaxel concentrations, and endothelial cell trans-
port of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with
Cremophor-based paclitaxel. Clin Cancer Res 12, 1317–1324.
[7] Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins
M, and O’Shaughnessy J (2005). Phase III trial of nanoparticle albumin-bound
paclitaxel compared with polyethylated castor oil–based paclitaxel in women
with breast cancer. J Clin Oncol 23, 7794–7803.
[8] Lobo C, Lopes G, Silva O, and Gluck S (2007). Paclitaxel albumin-bound par-
ticles (abraxane) in combination with bevacizumab with or without gemcitabine:
Neoplasia Vol. 10, No. 6, 2008 Anti-VEGF-A Enhances Nab-paclitaxel Therapy Volk et al. 621
early experience at the University of Miami/Braman Family Breast Cancer Insti-
tute. Biomed Pharmacother 61, 531–533.
[9] Ferrara N (2005). VEGF as a therapeutic target in cancer. Oncology 69 (Suppl 3),
11–16.
[10] Ferrara N, Hillan KJ, and Novotny W (2005). Bevacizumab (Avastin), a hu-
manized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys
Res Commun 333, 328–335.
[11] Wang J, Lou P, Lesniewski R, and Henkin J (2003). Paclitaxel at ultra low con-
centrations inhibits angiogenesis without affecting cellular microtubule assem-
bly. Anticancer Drugs 14, 13–19.
[12] Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, and Sledge
GW Jr (2001). The antiangiogenic property of docetaxel is synergistic with a
recombinant humanized monoclonal antibody against vascular endothelial
growth factor or 2-methoxyestradiol but antagonized by endothelial growth fac-
tors. Cancer Res 61, 3369–3372.
[13] Guo XL, Lin GJ, Zhao H, Gao Y, Qian LP, Xu SR, Fu LN, Xu Q, and Wang JJ
(2003). Inhibitory effects of docetaxel on expression of VEGF, bFGF and MMPs
of LS174T cell. World J Gastroenterol 9, 1995–1998.
[14] Lennernas B, Albertsson P, Lennernas H, and Norrby K (2003). Chemotherapy
and antiangiogenesis-drug–specific, dose-related effects. Acta Oncol 42, 294–303.
[15] Myoung H, Hong SD, Kim YY, Hong SP, and Kim MJ (2001). Evaluation of
the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the
xenotransplanted oral squamous cell carcinoma. Cancer Lett 163, 191–200.
[16] McDaid HM, Lopez-Barcons L, Grossman A, Lia M, Keller S, Pérez-Soler R, and
Horwitz SB (2005). Enhancement of the therapeutic efficacy of taxol by the
mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing
human heterotransplants. Cancer Res 65, 2854–2860.
[17] Wild R, Dings RP, Subramanian I, and Ramakrishnan S (2004). Carboplatin
selectively induces the VEGF stress response in endothelial cells: potentiation
of antitumor activity by combination treatment with antibody to VEGF. Int J
Cancer 110, 343–351.
[18] Miyahara Y, Yoshida S, Motoyama S, Tateiwa Y, Hamana S, and Maruo T
(2004). Effect of cis-diammine dichloroplatinum on vascular endothelial growth
factor expression in uterine cervical carcinoma. Eur J Gynaecol Oncol 25, 33–39.
[19] Riedel F, Gotte K, Goessler U, Sadick H, and Hormann K (2004). Targeting
chemotherapy-induced VEGF up-regulation by VEGF antisense oligonucleo-
tides in HNSCC cell lines. Anticancer Res 24, 2179–2183.
[20] Lev DC, Ruiz M, Mills L, McGary EC, Price JE, and Bar-Eli M (2003). Da-
carbazine causes transcriptional up-regulation of interleukin 8 and vascular en-
dothelial growth factor in melanoma cells: a possible escape mechanism from
chemotherapy. Mol Cancer Ther 2, 753–763.
[21] Mills PJ, Parker B, Jones V, Adler KA, Perez CJ, Johnson S, Cohen-Zion M,
Marler M, Sadler GR, Dimsdale JE, et al. (2004). The effects of standard
anthracycline-based chemotherapy on soluble ICAM-1 and vascular endothelial
growth factor levels in breast cancer. Clin Cancer Res 10, 4998–5003.
[22] Huang Y and FanW (2002). IkappaB kinase activation is involved in regulation of
paclitaxel-induced apoptosis in human tumor cell lines.MolPharmacol 61, 105–113.
[23] Aoudjit F and Vuori K (2001). Integrin signaling inhibits paclitaxel-induced
apoptosis in breast cancer cells. Oncogene 20, 4995–5004.
[24] Bischof M, Abdollahi A, Gong P, Stoffregen C, Lipson KE, Debus JU, Weber
KJ, and Huber PE (2004). Triple combination of irradiation, chemotherapy
(pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and
tumor cells. Int J Radiat Oncol Biol Phys 60, 1220–1232.
[25] Vaupel P, Kelleher DK, and Hockel M (2001). Oxygen status of malignant tu-
mors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol
28, 29–35.
[26] Koukourakis MI, Simopoulos C, Polychronidis A, Perente S, Botaitis S,
Giatromanolaki A, and Sivridis E (2003). The effect of trastuzumab/docatexel
combination on breast cancer angiogenesis: dichotomus effect predictable by
the HIFI alpha/VEGF pre-treatment status? Anticancer Res 23, 1673–1680.
[27] Byrne AM, Bouchier-Hayes DJ, and Harmey JH (2005). Angiogenic and cell
survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med
9, 777–794.
[28] Castro-Rivera E, Ran S, Thorpe P, and Minna JD (2004). Semaphorin 3B
(SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165
antagonizes this effect. Proc Natl Acad Sci USA 101, 11432–11437.
[29] Fan F, Wey JS, McCarty MF, Belcheva A, Liu W, Bauer TW, Somcio RJ, Wu Y,
Hooper A, Hicklin DJ, et al. (2005). Expression and function of vascular en-
dothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene
24, 2647–2653.
[30] Fox SB, Turley H, Cheale M, Blazquez C, Roberts H, James N, Cook N, Harris
A, and Gatter K (2004). Phosphorylated KDR is expressed in the neoplastic and
stromal elements of human renal tumours and shuttles from cell membrane to
nucleus. J Pathol 202, 313–320.
[31] Bachelder RE, Crago A, Chung J, Wendt MA, Shaw LM, Robinson G, and
Mercurio AM (2001). Vascular endothelial growth factor is an autocrine sur-
vival factor for neuropilin-expressing breast carcinoma cells. Cancer Res 61,
5736–5740.
[32] Bachelder RE, Wendt MA, and Mercurio AM (2002). Vascular endothelial
growth factor promotes breast carcinoma invasion in an autocrine manner by
regulating the chemokine receptor CXCR4. Cancer Res 62, 7203–7206.
[33] Emanuel S, Gruninger RH, Fuentes-Pesquera A, Connolly PJ, Seamon JA, Hazel
S, Tominovich R, Hollister B, Napier C, D’Andrea MR, et al. (2004). A vascular
endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the
conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xeno-
graft models. Mol Pharmacol 66, 635–647.
[34] Sweeney P, Karashima T, Kim SJ, Kedar D, Mian B, Huang S, Baker C, Fan Z,
Hicklin DJ, Pettaway CA, et al. (2002). Anti–vascular endothelial growth factor
receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate
cancer xenografts via induction of endothelial cell apoptosis and reduction of
endothelial cell matrix metalloproteinase type 9 production. Clin Cancer Res
8, 2714–2724.
[35] Teicher BA, Menon K, Alvarez E, Shih C, and Faul MM (2002). Antiangiogenic
and antitumor effects of a protein kinase Cbeta inhibitor in human breast cancer
and ovarian cancer xenografts. Invest New Drugs 20, 241–251.
[36] Jain RK (2002). Tumor angiogenesis and accessibility: role of vascular endothe-
lial growth factor. Semin Oncol 29, 3–9.
[37] Sandler AB, Johnson DH, and Herbst RS (2004). Anti–vascular endothelial
growth factor monoclonals in non–small cell lung cancer. Clin Cancer Res 10,
4258s–4262s.
[38] Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, and Jain RK (2004).
Vascular normalization by vascular endothelial growth factor receptor 2 block-
ade induces a pressure gradient across the vasculature and improves drug pen-
etration in tumors. Cancer Res 64, 3731–3736.
[39] de Gramont A and Van Cutsem E (2005). Investigating the potential of beva-
cizumab in other indications: metastatic renal cell, non–small cell lung, pancre-
atic and breast cancer. Oncology 69 (Suppl 3), 46–56.
[40] Mancuso MR, Davis R, Norberg SM, O’Brien S, Sennino B, Nakahara T, Yao
VJ, Inai T, Brooks P, Freimark B, et al. (2006). Rapid vascular regrowth in
tumors after reversal of VEGF inhibition. J Clin Invest 116, 2610–2621.
[41] Whitehurst B, Bivens CM, Pickett B, Castro-Rivera E, and Ran S (2007). In-
hibition of tumor lymphangiogenesis by VEGF-A neutralizing antibody in
orthotopic breast tumors. Int J Cancer 121, 2181–2191.
[42] Price DJ, Miralem T, Jiang S, Steinberg R, and Avraham H (2001). Role of
vascular endothelial growth factor in the stimulation of cellular invasion and
signaling of breast cancer cells. Cell Growth Differ 12, 129–135.
[43] Wu Y, Hooper AT, Zhong Z, Witte L, Bohlen P, Rafii S, and Hicklin DJ
(2006). The vascular endothelial growth factor receptor (VEGFR-1) supports
growth and survival of human breast carcinoma. Int J Cancer 119, 1519–1529.
[44] Harmey JH and Bouchier-Hayes D (2002). Vascular endothelial growth factor
(VEGF), a survival factor for tumour cells: implications for anti-angiogenic ther-
apy. Bioessays 24, 280–283.
[45] Mercurio AM, Lipscomb EA, and Bachelder RE (2005). Non-angiogenic
functions of VEGF in breast cancer. J Mammary Gland Biol Neoplasia 10,
283–290.
[46] Ng SS, Sparreboom A, Shaked Y, Lee C, Man S, Desai N, Soon-Shiong P, Figg
WD, and Kerbel RS (2006). Influence of formulation vehicle on metronomic
taxane chemotherapy: albumin-bound versus Cremophor EL-based paclitaxel.
Clin Cancer Res 12, 4331–4338.
[47] Nyman DW, Campbell KJ, Hersh E, Long K, Richardson K, Trieu V, Desai N,
Hawkins MJ, and Von Hoff DD (2005). Phase I and pharmacokinetics trial of
ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced
nonhematologic malignancies. J Clin Oncol 23, 7785–7793.
[48] Rizvi NA, Riely GJ, Azzoli CG, Miller VA, Ng KK, Fiore J, Chia G, Brower M,
Heelan R, Hawkins MJ, et al. (2008). Phase I/II trial of weekly intravenous
130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage
IV non–small-cell lung cancer. J Clin Oncol 26, 639–643.
[49] Link JS, Waisman JR, Nguyen B, and Jacobs CI (2007). Bevacizumab and
albumin-bound paclitaxel treatment in metastatic breast cancer. Clin Breast
Cancer 7, 779–783.
622 Anti-VEGF-A Enhances Nab-paclitaxel Therapy Volk et al. Neoplasia Vol. 10, No. 6, 2008
[50] Dadiani M, Kalchenko V, Yosepovich A, Margalit R, Hassid Y, Degani H, and
Seger D (2006). Real-time imaging of lymphogenic metastasis in orthotopic
human breast cancer. Cancer Res 66, 8037–8041.
[51] Liu W, Ahmad SA, Reinmuth N, Shaheen RM, Jung YD, Fan F, and Ellis LM
(2000). Endothelial cell survival and apoptosis in the tumor vasculature. Apop-
tosis 5, 323–328.
[52] Beierle EA, Nagaram A, Dai W, Iyengar M, and Chen MK (2005). VEGF-
mediated survivin expression in neuroblastoma cells. J Surg Res 127, 21–28.
[53] Kerbel RS (2006). Antiangiogenic therapy: a universal chemosensitization strat-
egy for cancer? Science 312, 1171–1175.
[54] Inoue K, Slaton JW, Davis DW, Hicklin DJ, McConkey DJ, Karashima T,
Radinsky R, and Dinney CP (2000). Treatment of human metastatic transi-
tional cell carcinoma of the bladder in a murine model with the anti–vascular
endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel.
Clin Cancer Res 6, 2635–2643.
[55] Gerber HP and Ferrara N (2005). Pharmacology and pharmacodynamics of
bevacizumab as monotherapy or in combination with cytotoxic therapy in pre-
clinical studies. Cancer Res 65, 671–680.
[56] Cohn DE, Valmadre S, Resnick KE, Eaton LA, Copeland LJ, and Fowler JM
(2006). Bevacizumab and weekly taxane chemotherapy demonstrates activity in
refractory ovarian cancer. Gynecol Oncol 102, 134–139.
[57] Cohen MH, Gootenberg J, Keegan P, and Pazdur R (2007). FDA drug approval
summary: bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line
treatment of advanced/metastatic recurrent nonsquamous non–small cell lung
cancer. Oncologist 12, 713–718.
[58] Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R,
and Johnson DH (2006). Paclitaxel-carboplatin alone or with bevacizumab for
non–small-cell lung cancer. N Engl J Med 355, 2542–2550.
[59] Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T,
Cella D, and Davidson NE (2007). Paclitaxel plus bevacizumab versus paclitaxel
alone for metastatic breast cancer. N Engl J Med 357, 2666–2676.
[60] Luzzi KJ, MacDonald IC, Schmidt EE, Kerkvliet N, Morris VL, Chambers AF,
and Groom AC (1998). Multistep nature of metastatic inefficiency: dormancy
of solitary cells after successful extravasation and limited survival of early micro-
metastases. Am J Pathol 153, 865–873.
[61] Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, Hicklin DJ,
Chaplin D, Foster FS, Benezra R, et al. (2006). Therapy-induced acute re-
cruitment of circulating endothelial progenitor cells to tumors. Science 313,
1785–1787.
[62] Jain RK, Tong RT, and Munn LL (2007). Effect of vascular normalization by anti-
angiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic
metastasis: insights from a mathematical model. Cancer Res 67, 2729–2735.
[63] Folkins C, Man S, Xu P, Shaked Y, Hicklin DJ, and Kerbel RS (2007). Anti-
cancer therapies combining antiangiogenic and tumor cell cytotoxic effects re-
duce the tumor stem–like cell fraction in glioma xenograft tumors. Cancer Res
67, 3560–3564.
[64] Hirakawa S, Kodama S, Kunstfeld R, Kajiya K, Brown LF, and Detmar M
(2005). VEGF-A induces tumor and sentinel lymph node lymphangiogenesis
and promotes lymphatic metastasis. J Exp Med 201, 1089–1099.
[65] Henderson IC and Bhatia V (2007). Nab-paclitaxel for breast cancer: a new
formulation with an improved safety profile and greater efficacy. Expert Rev
Anticancer Ther 7, 919–943.
Neoplasia Vol. 10, No. 6, 2008 Anti-VEGF-A Enhances Nab-paclitaxel Therapy Volk et al. 623
